@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_head { this: np:hasAssertion dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_assertion; np:hasProvenance dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_provenance; np:hasPublicationInfo dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_publicationInfo; a np:Nanopublication . dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_assertion a np:Assertion . dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_provenance a np:Provenance . dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_publicationInfo a np:PublicationInfo . } dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_assertion { miriam-gene:8932 a ncit:C16612 . lld:C1704272 a ncit:C7057 . dgn-gda:DGNbb1c28f062c5797c75a90febaf83701c sio:SIO_000628 miriam-gene:8932, lld:C1704272; a sio:SIO_001121 . } dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_provenance { dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_assertion dcterms:description "[The results of these experiments demonstrated that (1) the activity of DNMTs was twofold to threefold higher in cancer cell lines and cancer tissues, as compared with a benign prostate epithelium cell line (BPH-1) and benign prostatic hyperplasia (BPH) tissues; (2) MBD2 activity was lacking in prostate cancer cell lines but present in BPH-1 cells; (3) immunohistochemical analyses exhibited higher expression of DNMT1 in all prostate cancer cell lines and cancer tissues, as compared with BPH-1 cell lines and BPH tissues; (4) MBD2 protein expression was significantly higher in BPH-1 cells and lacking in prostate cancer cell lines and, in BPH tissues, MBD2 protein expression was poorly observed, as compared with no expression in prostate cancer tissues; and (5) mRNA expression for DNMT1 was upregulated in prostate cancer, as compared with BPH-1, and mRNA expression for MBD2 was found to be significantly expressed in all cases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:11870882; prov:wasDerivedFrom dgn-void:befree-20150227; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20150227 pav:importedOn "2015-02-27"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP811879.RAJKjB6yFX_hWc5F53ctuEv3I4XtXb8Y78TJIVxtkjHgE130_publicationInfo { this: dcterms:created "2015-08-25T14:45:52+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v3.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v3.0.0" . }